{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:46:54Z","timestamp":1787687214110,"version":"build-2784847793"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8,1]]},"DOI":"10.1093\/rheumatology\/kev002","type":"journal-article","created":{"date-parts":[[2015,3,10]],"date-time":"2015-03-10T01:04:14Z","timestamp":1425949454000},"page":"1443-1447","source":"Crossref","is-referenced-by-count":67,"title":["Prediction and impact of attacks of Raynaud\u2019s phenomenon, as judged by patient perception"],"prefix":"10.1093","volume":"54","author":[{"given":"Michael","family":"Hughes","sequence":"first","affiliation":[{"name":"Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Snapir","sequence":"additional","affiliation":[{"name":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wilkinson","sequence":"additional","affiliation":[{"name":"Research and Development, Salford Royal NHS Foundation Trust, Salford, UK and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Snapir","sequence":"additional","affiliation":[{"name":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick M.","family":"Wigley","sequence":"additional","affiliation":[{"name":"Johns Hopkins Scleroderma Center, Division of Rheumatology, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane L.","family":"Herrick","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,3,9]]},"reference":[{"key":"key\n\t\t\t\t2019031305261205600_kev002-B1","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Clinical practice. Raynaud\u2019s phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B2","doi-asserted-by":"crossref","first-page":"469\u221279","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B3","doi-asserted-by":"crossref","first-page":"1953\u221262","DOI":"10.1002\/art.37988","article-title":"Review: evidence that systemic sclerosis is a vascular disease","volume":"65","author":"Matucci-Cerinic","year":"2013","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B4","first-page":"CD006687","article-title":"Oral vasodilators for primary Raynaud\u2019s phenomenon","volume":"11;7","author":"Stewart","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B5","first-page":"CD002069","article-title":"Calcium channel blockers for primary Raynaud\u2019s phenomenon","volume":"1","author":"Ennis","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B6","doi-asserted-by":"crossref","first-page":"2410\u221220","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud\u2019s phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B7","doi-asserted-by":"crossref","first-page":"206\u221210","DOI":"10.1097\/RHU.0b013e31817a2485","article-title":"Health-related quality of life in primary Raynaud phenomenon","volume":"14","author":"De Angelis","year":"2008","journal-title":"J Clin Rheumatol"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B8","doi-asserted-by":"crossref","first-page":"870\u22127","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud\u2019s phenomenon: a randomized, controlled trial","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B9","first-page":"1101\u22128","article-title":"Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud\u2019s phenomenon. Results from a randomized clinical trial with 1-year follow-up","volume":"160","author":"Raynaud\u2019s Treatment Study Investigators","year":"2000","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B10","doi-asserted-by":"crossref","first-page":"999\u22121004","DOI":"10.1093\/rheumatology\/kel038","article-title":"Iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol","volume":"45","author":"Milio","year":"2006","journal-title":"Rheumatology"},{"key":"key\n\t\t\t\t2019031305261205600_kev002-B11","doi-asserted-by":"crossref","first-page":"2420\u22128","DOI":"10.1093\/rheumatology\/keq291","article-title":"Efficacy of tadalafil in secondary Raynaud\u2019s phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial","volume":"49","author":"Shenoy","year":"2010","journal-title":"Rheumatology"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/54\/8\/1443\/28057671\/kev002.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T09:26:21Z","timestamp":1552469181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/54\/8\/1443\/1799054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,9]]},"references-count":11,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,3,9]]},"published-print":{"date-parts":[[2015,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/kev002","relation":{},"ISSN":["1462-0332","1462-0324"],"issn-type":[{"value":"1462-0332","type":"electronic"},{"value":"1462-0324","type":"print"}],"subject":[],"published-other":{"date-parts":[[2015,8]]},"published":{"date-parts":[[2015,3,9]]}}}